PRECISION BIOSCIENCES INCDTILEarnings & Financial Report
Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.
DTIL Q4 FY2025 Key Financial Metrics
Revenue
$34.2M
Gross Profit
N/A
Operating Profit
$12.5M
Net Profit
$20.1M
Gross Margin
N/A
Operating Margin
36.6%
Net Margin
58.9%
YoY Growth
5261.1%
EPS
$2.62
PRECISION BIOSCIENCES INC Q4 FY2025 Financial Summary
PRECISION BIOSCIENCES INC reported revenue of $34.2M (up 5261.1% YoY) for Q4 FY2025, with a net profit of $20.1M (up 213.5% YoY) (58.9% margin).
Key Financial Metrics
| Total Revenue | $34.2M |
|---|---|
| Net Profit | $20.1M |
| Gross Margin | N/A |
| Operating Margin | 36.6% |
| Report Period | Q4 FY2025 |
PRECISION BIOSCIENCES INC Annual Revenue by Year
PRECISION BIOSCIENCES INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $34.3M).
PRECISION BIOSCIENCES INC Quarterly Revenue & Net Profit History
PRECISION BIOSCIENCES INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $34.2M | +5261.1% | $20.1M | 58.9% |
| Q3 FY2025 | $13.0K | -97.7% | $-21.8M | -167476.9% |
| Q2 FY2025 | $18.0K | -100.0% | $-23.5M | -130666.7% |
| Q1 FY2025 | $29.0K | -99.8% | $-20.6M | -70913.8% |
| Q4 FY2024 | $638.0K | -90.9% | N/A | N/A |
| Q3 FY2024 | $576.0K | -95.6% | $-16.4M | -2851.6% |
| Q2 FY2024 | $49.9M | +152.2% | $32.7M | 65.6% |
| Q1 FY2024 | $17.6M | +100.3% | $8.6M | 48.8% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17.6M | $49.9M | $576000 | $638000 | $29000 | $18000 | $13000 | $34.2M |
| YoY Growth | 100.3% | 152.2% | -95.6% | -90.9% | -99.8% | -100.0% | -97.7% | 5261.1% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $184.7M | $165.8M | $153.3M | $136.4M | $124.4M | $108.9M | $93.5M | $154.4M |
| Liabilities | $147.5M | $91.1M | $88.4M | $80.0M | $75.1M | $74.9M | $76.9M | $62.2M |
| Equity | $37.2M | $74.7M | $64.9M | $56.4M | $49.3M | $34.1M | $16.6M | $92.2M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-19.0M | $-14.9M | $-5.9M | $-58.4M | $-19.1M | $-20.3M | $-15.3M | $-11.3M |